RXi Pharmaceuticals

RXi Pharmaceuticals announced Wednesday it is looking at possible merger-and-acquisition options to advance its clinical pipeline.

RXi Pharmaceuticals Corporation announced this week a phase 2 clinical trial to evaluate the safety and clinical activity of Samcyprone, an immunomodulator that could help clear cutaneous warts.

RXi Pharmaceuticals of Marlborough said Thursday it has begun its first clinical trial of a compound to evaluate its ability to prevent retinal scarring.

RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, has been granted a Chinese patent for the composition and methods of use for compounds that may be used to treat dermal scarring, the company announced Monday.

RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, has cut second quarter losses and secured an additional year of cash as it continues to advance its clinical and preclinical pipeline.

RXi Pharmaceuticals of Marlborough said last week it is making a public offering of common stock and warrants.

RXi Pharmaceuticals of Marlborough, which is pushing toward regulatory approval of its signature anti-scarring drug, saw a slight increase in revenue and cut its losses in the first quarter, the company said Wednesday.

A drug being developed by RXi Pharmaceuticals of Marlborough to treat patients with malignant melanoma has secured “orphan” status from the federal government, allowing RXi to seek more incentives to bring it to market, the company announced.

RXi Pharmaceuticals of Marlborough, which is pushing toward federal approval of its initial products, saw 8.3-percent revenue growth in the final quarter of 2014 while paring its quarterly loss over the fourth quarter of 2013.

Marlborough-based biotechnology firm RXi Pharmaceuticals said three-month observations have confirmed the effectiveness of its first product candidate, RXI-109, in the treatment of post-surgical scars.